Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recall study of rivastigmine for ECT-induced interictal delirium in late-life depression
NL-OMON47261Recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of rivastigmine in delirium and major depressive episode (MDE) (2 arms), sponsored by Amsterdam UMC, location VUmc. Primary endpoints: Delirium severity after rivastigmine versus placebo and Cognitive functioning after rivastigmine versus placebo. Started Aug 2017; status: recruiting.
02
Drugs
rivastigmine
03
Conditions
deliriummajor depressive episode (MDE)
Beyond the preview
Go deeper on NL-OMON47261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47261.